All ICD10 Codes

DRG 837

Medical DRG

Chemotherapy with Acute Leukemia as Secondary Diagnosis or with High Dose Chemotherapy Agent with MCC

TypeMedicalMDC17Dx Codes36

What is MS-DRG 837?

MS-DRG 837 is a Medical Medicare Severity Diagnosis Related Group under Major Diagnostic Category 17 (MDC 17) with a Major Complication or Comorbidity (MCC). It maps to 36 ICD-10-CM diagnosis codes. For FY 2026 it carries a relative weight of 4.8043 with a geometric mean length of stay of 10.2 days and an arithmetic mean of 14.9 days. Hospitals use this grouping to determine reimbursement for inpatient stays under Medicare.

Classification
Medical DRG
Diagnosis-driven grouping
MDC
Major Diagnostic Category 17
Linked Codes
36 diagnosis
10 procedure
Billable Dx
100%
36 of 36 shown

FY 2026 Payment Data

Official values from Table 5 of the FY 2026 IPPS Final Rule (CMS).

Relative Weight
4.8043
Payment multiplier vs. average case (1.0)
Geometric Mean LOS
10.2 days
Used for transfer payment calculations
Arithmetic Mean LOS
14.9 days
Average length of stay
Post-Acute Transfer
No
Not subject to the transfer policy

Linked ICD-10-PCS Procedure Mappings

  • 3E03002

    Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach

    BillableSection 3
  • 3E03302

    Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach

    BillableSection 3
  • 3E04002

    Introduction of High-dose Interleukin-2 into Central Vein, Open Approach

    BillableSection 3
  • 3E04302

    Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach

    BillableSection 3
  • 3E05002

    Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach

    BillableSection 3
  • 3E05302

    Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach

    BillableSection 3
  • 3E06002

    Introduction of High-dose Interleukin-2 into Central Artery, Open Approach

    BillableSection 3
  • 3E06302

    Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach

    BillableSection 3
  • 3E0R302

    Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach

    BillableSection 3
  • 3E0S302

    Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach

    BillableSection 3

Linked ICD-10-CM Diagnosis Mappings

  • C91.00

    Acute lymphoblastic leukemia not having achieved remission

    BillableChapter 2
  • C91.01

    Acute lymphoblastic leukemia, in remission

    BillableChapter 2
  • C91.02

    Acute lymphoblastic leukemia, in relapse

    BillableChapter 2
  • C92.00

    Acute myeloblastic leukemia, not having achieved remission

    BillableChapter 2
  • C92.01

    Acute myeloblastic leukemia, in remission

    BillableChapter 2
  • C92.02

    Acute myeloblastic leukemia, in relapse

    BillableChapter 2
  • C92.40

    Acute promyelocytic leukemia, not having achieved remission

    BillableChapter 2
  • C92.41

    Acute promyelocytic leukemia, in remission

    BillableChapter 2
  • C92.42

    Acute promyelocytic leukemia, in relapse

    BillableChapter 2
  • C92.50

    Acute myelomonocytic leukemia, not having achieved remission

    BillableChapter 2
  • C92.51

    Acute myelomonocytic leukemia, in remission

    BillableChapter 2
  • C92.52

    Acute myelomonocytic leukemia, in relapse

    BillableChapter 2
  • C92.60

    Acute myeloid leukemia with 11q23-abnormality not having achieved remission

    BillableChapter 2
  • C92.61

    Acute myeloid leukemia with 11q23-abnormality in remission

    BillableChapter 2
  • C92.62

    Acute myeloid leukemia with 11q23-abnormality in relapse

    BillableChapter 2
  • C92.A0

    Acute myeloid leukemia with multilineage dysplasia, not having achieved remission

    BillableChapter 2
  • C92.A1

    Acute myeloid leukemia with multilineage dysplasia, in remission

    BillableChapter 2
  • C92.A2

    Acute myeloid leukemia with multilineage dysplasia, in relapse

    BillableChapter 2
  • C93.00

    Acute monoblastic/monocytic leukemia, not having achieved remission

    BillableChapter 2
  • C93.01

    Acute monoblastic/monocytic leukemia, in remission

    BillableChapter 2
  • C93.02

    Acute monoblastic/monocytic leukemia, in relapse

    BillableChapter 2
  • C94.00

    Acute erythroid leukemia, not having achieved remission

    BillableChapter 2
  • C94.01

    Acute erythroid leukemia, in remission

    BillableChapter 2
  • C94.02

    Acute erythroid leukemia, in relapse

    BillableChapter 2
  • C94.20

    Acute megakaryoblastic leukemia not having achieved remission

    BillableChapter 2
  • C94.21

    Acute megakaryoblastic leukemia, in remission

    BillableChapter 2
  • C94.22

    Acute megakaryoblastic leukemia, in relapse

    BillableChapter 2
  • C94.40

    Acute panmyelosis with myelofibrosis not having achieved remission

    BillableChapter 2
  • C94.41

    Acute panmyelosis with myelofibrosis, in remission

    BillableChapter 2
  • C94.42

    Acute panmyelosis with myelofibrosis, in relapse

    BillableChapter 2
  • C95.00

    Acute leukemia of unspecified cell type not having achieved remission

    BillableChapter 2
  • C95.01

    Acute leukemia of unspecified cell type, in remission

    BillableChapter 2
  • C95.02

    Acute leukemia of unspecified cell type, in relapse

    BillableChapter 2
  • Z08

    Encounter for follow-up examination after completed treatment for malignant neoplasm

    BillableChapter 21
  • Z51.11

    Encounter for antineoplastic chemotherapy

    BillableChapter 21
  • Z51.12

    Encounter for antineoplastic immunotherapy

    BillableChapter 21